← feed

Is NCT03413124 results overdue?

Yes — results are overdue. Primary completion was 2018-02-17; the FDAAA-801 reporting deadline (2019-02-17) passed 2727 days ago and no results are posted on ClinicalTrials.gov.

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

NCT IDNCT03413124 ↗
SponsorMadrigal Pharmaceuticals, Inc. (INDUSTRY)
Public issuerMADRIGAL PHARMACEUTICALS, INC. — MDGL (CIK 0001157601) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-02-17 (ACTUAL)
Reporting deadline2019-02-17 (completion + 365d)
Days overdue2727
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 e4502866a9e81410… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03413124. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →